STOCKHOLM, SWEDEN – September 28, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented new preclinical results that provide further support for the company's most advanced drug candidate golexanolone in the treatment of the rare autoimmune disease primary biliary cholangitis (PBC). Study data show that golexanolone has a significant positive effect on extreme fatigue in a validated test model. Umecrine Cognition plans to initiate a phase 2 clinical trial of golexanolone in patients suffering from PBC in the near future.
Karolinska Development (Nasdaq Stockholm: KDEV) announces that its portfolio company Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy. The results will be presented at The Liver Meeting Digital Experience™ on November 13–16, 2020.